<DOC>
	<DOCNO>NCT02565888</DOCNO>
	<brief_summary>This study aim provide evidence 150mg cobicistat effect pharmacokinetics daclatasvir 30mg QD 100mg ritonavir , give together atazanavir 300mg .</brief_summary>
	<brief_title>A Drug-drug Interaction Study Between Daclatasvir Atazanavir/Ritonavir Atazanavir/Cobicistat</brief_title>
	<detailed_description>Approximately 20-25 % total number HIV-infected patient co-infected HCV translate 6-8 million person worldwide . Combined treatment HIV HCV complicate risk drug-drug interaction direct act antiviral agent ( DAAs ) HCV antiretroviral agent HIV substrates cytochrome P450 ( CYP450 ) various membrane transporter , also capacity influence system . A careful selection appropriate regimen need adjusted dos key optimal treatment viral infection . Daclatasvir recently approve anti-HCV agent CYP3A4 substrate affect CYP450 . It also moderate inhibitor various membrane transporter organic anion-transporting polypeptide ( OATP1B1 ) , P-glycoprotein ( P-gP ) , organic cation transporter ( OCT2 ) . Atazanavir/ritonavir one prefer antiretroviral agent international guideline . Ritonavir use boost agent base inhibitory effect CYP3A . This also inhibit CYP3A-mediated metabolism daclatasvir atazanavir/ritonavir combine daclatasvir , recommend reduce dose daclatasvir 60mg QD 30mg QD . Cobicistat recently approve alternative booster atazanavir dose 150mg QD . It expect cobicistat inhibit CYP3A mediate metabolism daclatasvir similar manner ritonavir , clinical data support . As cobicistat lack adverse event associate ritonavir use , use cobicistat , include booster atazanavir , likely increase . This study aim provide evidence 150mg cobicistat effect pharmacokinetics daclatasvir 30mg QD 100mg ritonavir , give together atazanavir 300mg .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Anti-Retroviral Agents</mesh_term>
	<criteria>1 . Subject least 18 old 55 year screen . 2 . Subject smoke 10 cigarette , 2 cigar , 2 pipe per day least 3 month prior Day 1 . 3 . Subject Quetelet Index ( Body Mass Index ) 18 30 kg/m2 , extremes include . 4 . Subject able willing sign Informed Consent Form prior screen evaluation . 5 . Subject good ageappropriate health condition establish medical history , physical examination , electrocardiography , result biochemistry , hematology urinalysis test within 4 week prior day 1 . Results biochemistry , hematology urinalysis test within laboratory 's reference range ( see Appendix A ) . If laboratory result within reference range , subject include condition Investigator judge deviation clinically relevant . This clearly record . 6 . Subject normal blood pressure pulse rate , accord Investigator 's judgment . 1 . Creatinine clearance 60mL/min . 2 . Documented history sensitivity/idiosyncrasy medicinal product excipients . 3 . Positive HIV test . 4 . Positive hepatitis B C test . 5 . Pregnant female ( confirm hCG test perform less 4 week day 1 ) breastfeed female . Female subject childbearing potential without adequate contraception , e.g . hysterectomy , bilateral tubal ligation , ( nonhormonal ) intrauterine device , total abstinence , double barrier method , two year postmenopausal . They must agree take precaution order prevent pregnancy throughout entire conduct study . 6 . Therapy drug ( two week precede Day 1 ) , except acetaminophen ( max 2 gram/day ) . 7 . Relevant history presence pulmonary disorder ( especially COPD ) , cardiovascular disorder , neurological disorder ( especially seizures migraine ) , psychiatric disorder , gastrointestinal disorder , renal hepatic disorder ( clinically relevant increase ALAT/ASAT hyperbilirubinemia ) hormonal disorder ( especially diabetes mellitus ) , coagulation disorder . 8 . Relevant history current condition might interfere drug absorption , distribution , metabolism excretion . 9 . History current abuse drug , alcohol solvent . 10 . Inability understand nature extent study procedure require . 11 . Participation drug study within 60 day prior Day 1 . 12 . Donation blood within 60 day prior Day 1 . 13 . Febrile illness within 3 day Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HIV</keyword>
	<keyword>atazanavir</keyword>
	<keyword>ritonavir</keyword>
	<keyword>daclatasvir</keyword>
	<keyword>cobicistat</keyword>
</DOC>